Biopharma Outsourcing on the Rise!
The Biopharmaceutical Contract Manufacturing Market is projected to skyrocket from USD 11.23 Billion  in 2025 to USD 26.93 Billion by 2035 📈  that’s a solid CAGR of 8.8%.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://www.futuremarketinsights.com/reports/sample/rep-gb-2982

💡 Why the surge?

• Rising complexity of biologics 🧬
• Limited in-house capabilities at pharma firms
• Strong demand for mammalian-based expression systems (72.5% share in 2025)
• Outsourcing for monoclonal antibodies, vaccines, & gene therapies

🌏 Hotspots: China, India, Japan = fastest-growing markets
🏭 Key moves:

• Thermo Fisher Scientific expands biologics facility in Hangzhou 🇨🇳
• Sartorius integrates single-use bioreactors for speed & scale
• FDA CMC 2025 guideline boosts faster approvals

📊 Future Outlook: Mammalian systems remain dominant; microbial-based platforms gain traction for cost-sensitive biologics.